No adverse event; First Moderna dose on 27Sep2022 Second dose Date of administration of vaccine 24Feb2023; 7 doses of Moderna monovalent lot number 038A22A, expiration date 10.30.2022, was administered to patients; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First Moderna dose on 27Sep2022 Second dose Date of administration of vaccine 24Feb2023), EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 038A22A, expiration date 10.30.2022, was administered to patients) and NO ADVERSE EVENT (No adverse event) in a 43-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 038A22A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 27-Sep-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 24-Feb-2023 at 12:58 PM, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to .5 milliliter. On 24-Feb-2023 at 12:58 PM, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First Moderna dose on 27Sep2022 Second dose Date of administration of vaccine 24Feb2023) and EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 038A22A, expiration date 10.30.2022, was administered to patients). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First Moderna dose on 27Sep2022 Second dose Date of administration of vaccine 24Feb2023), EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 038A22A, expiration date 10.30.2022, was administered to patients) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First Moderna dose on 27Sep2022 Second dose Date of administration of vaccine 24Feb2023) and EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 038A22A, expiration date 10.30.2022, was administered to patients).    It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. No concomitant medications was reported.  The vaccine was frozen with no known temperature excursion before being thawed. The vial was initially stored in the refrigerator on 24-Feb-2023. The vial had not undergone any temperature excursions.  No treatment medications was reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-712765, US-MODERNATX, INC.-MOD-2023-712698, US-MODERNATX, INC.-MOD-2023-712700, US-MODERNATX, INC.-MOD-2023-712708, US-MODERNATX, INC.-MOD-2023-712760, US-MODERNATX, INC.-MOD-2023-712766 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 24-Feb-2023: Non significant live follow up received: Vaccination time added.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-712765: US-MODERNATX, INC.-MOD-2023-712698: US-MODERNATX, INC.-MOD-2023-712700: US-MODERNATX, INC.-MOD-2023-712760: US-MODERNATX, INC.-MOD-2023-712766: